Literature DB >> 25527826

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Xavier Ayrignac1, Clarisse Carra-Dalliere1, Nicolas Menjot de Champfleur2, Christian Denier3, Patrick Aubourg4, Celine Bellesme4, Giovanni Castelnovo5, Jean Pelletier6, Bertrand Audoin6, Elsa Kaphan6, Jerome de Seze7, Nicolas Collongues7, Frederic Blanc7, Jean-Baptiste Chanson7, Eloi Magnin8, Eric Berger8, Sandra Vukusic9, Francoise Durand-Dubief9, Jean-Philippe Camdessanche10, Mickael Cohen11, Christine Lebrun-Frenay11, David Brassat12, Michel Clanet13, Patrick Vermersch14, Helene Zephir14, Olivier Outteryck14, Sandrine Wiertlewski15, David-Axel Laplaud15, Jean-Christophe Ouallet16, Bruno Brochet16, Cyril Goizet16, Marc Debouverie17, Sophie Pittion17, Gilles Edan18, Véronique Deburghgraeve18, Emmanuelle Le Page18, Christophe Verny19, Patrizia Amati-Bonneau19, Dominique Bonneau19, Didier Hannequin20, Lucie Guyant-Maréchal21, Nathalie Derache22, Gilles Louis Defer22, Thibault Moreau23, Maurice Giroud23, Anne Marie Guennoc24, Pierre Clavelou25, Frédérique Taithe25, Stephane Mathis26, Jean-Philippe Neau26, Laurent Magy27, Jean Louis Devoize28, Marc Bataillard7, Julien Masliah-Planchon29, Imen Dorboz30, Elisabeth Tournier-Lasserve31, Thierry Levade32, Odile Boespflug Tanguy30, Pierre Labauge33.   

Abstract

Inherited white matter diseases are rare and heterogeneous disorders usually encountered in infancy. Adult-onset forms are increasingly recognized. Our objectives were to determine relative frequencies of genetic leukoencephalopathies in a cohort of adult-onset patients and to evaluate the effectiveness of a systematic diagnostic approach. Inclusion criteria of this retrospective study were: (i) symmetrical involvement of white matter on the first available brain MRI; (ii) age of onset above 16 years. Patients with acquired diseases were excluded. Magnetic resonance imaging analysis identified three groups (vascular, cavitary and non-vascular/non-cavitary) in which distinct genetic and/or biochemical testing were realized. One hundred and fifty-four patients (male/female = 60/94) with adult-onset leukoencephalopathies were identified. Mean age of onset was 38.6 years. In the vascular group, 41/55 patients (75%) finally had a diagnosis [including CADASIL (cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy, n = 32) and COL4A1 mutation, n = 7]. In the cavitary group, 13/17 (76%) patients had a diagnosis of EIF2B-related disorder. In the third group (n = 82), a systematic biological screening allowed a diagnosis in 23 patients (28%) and oriented direct genetic screening identified 21 additional diseases (25.6%). Adult-onset genetic leukoencephalopathies are a rare but probably underestimated entity. Our study confirms the use of a magnetic resonance imaging-based classification with a final diagnosis rate of 64% (98/154) cases.
© The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  MRI; genetic; leukodystrophy; leukoencephalopathies; metabolic

Mesh:

Year:  2014        PMID: 25527826     DOI: 10.1093/brain/awu353

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  15 in total

Review 1.  Vascular Parkinsonism: deconstructing a syndrome.

Authors:  Joaquin A Vizcarra; Anthony E Lang; Kapil D Sethi; Alberto J Espay
Journal:  Mov Disord       Date:  2015-05-21       Impact factor: 10.338

Review 2.  Posterior fossa involvement in the diagnosis of adult-onset inherited leukoencephalopathies.

Authors:  Xavier Ayrignac; Clemence Boutiere; Clarisse Carra-Dalliere; Pierre Labauge
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

Review 3.  The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Authors:  Ruth Geraldes; Olga Ciccarelli; Frederik Barkhof; Nicola De Stefano; Christian Enzinger; Massimo Filippi; Monika Hofer; Friedemann Paul; Paolo Preziosa; Alex Rovira; Gabriele C DeLuca; Ludwig Kappos; Tarek Yousry; Franz Fazekas; Jette Frederiksen; Claudio Gasperini; Jaume Sastre-Garriga; Nikos Evangelou; Jacqueline Palace
Journal:  Nat Rev Neurol       Date:  2018-03-09       Impact factor: 42.937

Review 4.  CSF1R-related leukoencephalopathy: A major player in primary microgliopathies.

Authors:  Takuya Konno; Koji Kasanuki; Takeshi Ikeuchi; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Neurology       Date:  2018-11-14       Impact factor: 9.910

Review 5.  Clinical and research applications of magnetic resonance imaging in the study of CADASIL.

Authors:  Dorothee Schoemaker; Yakeel T Quiroz; Heirangi Torrico-Teave; Joseph F Arboleda-Velasquez
Journal:  Neurosci Lett       Date:  2019-01-08       Impact factor: 3.046

6.  POLG-Associated Ataxia Presenting as a Fragile X Tremor/Ataxia Phenocopy Syndrome.

Authors:  Martin Paucar; Martin Engvall; Lisa Gordon; Emma Tham; Matthis Synofzik; Per Svenningsson
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

Review 7.  Adulthood leukodystrophies.

Authors:  Wolfgang Köhler; Julian Curiel; Adeline Vanderver
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

Review 8.  [Metabolic induced changes of the central nervous system].

Authors:  W Reith; U Yilmaz; R Mühl-Bennighaus; A Haußmann
Journal:  Radiologe       Date:  2018-12       Impact factor: 0.635

9.  Archetypal NOTCH3 mutations frequent in public exome: implications for CADASIL.

Authors:  Julie W Rutten; Hans G Dauwerse; Gido Gravesteijn; Martine J van Belzen; Jeroen van der Grond; James M Polke; Manuel Bernal-Quiros; Saskia A J Lesnik Oberstein
Journal:  Ann Clin Transl Neurol       Date:  2016-09-28       Impact factor: 4.511

10.  Use of sodium 4-phenylbutyrate to define therapeutic parameters for reducing intracerebral hemorrhage and myopathy in Col4a1 mutant mice.

Authors:  Genki Hayashi; Cassandre Labelle-Dumais; Douglas B Gould
Journal:  Dis Model Mech       Date:  2018-07-04       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.